These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27128291)

  • 1. Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference.
    Ebner N; von Haehling S
    J Cachexia Sarcopenia Muscle; 2016 Mar; 7(1):90-4. PubMed ID: 27128291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highlights from the 9th Cachexia Conference.
    Ebner N; von Haehling S
    J Cachexia Sarcopenia Muscle; 2017 Jun; 8(3):508-511. PubMed ID: 28631415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silver linings on the horizon: highlights from the 10th Cachexia Conference.
    Ebner N; von Haehling S
    J Cachexia Sarcopenia Muscle; 2018 Feb; 9(1):176-182. PubMed ID: 29417752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference.
    Ebner N; Anker SD; von Haehling S
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):218-225. PubMed ID: 30920774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 12th Cachexia Conference.
    Ebner N; Anker SD; von Haehling S
    J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):274-285. PubMed ID: 32049447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies.
    Ebner N; Steinbeck L; Doehner W; Anker SD; von Haehling S
    J Cachexia Sarcopenia Muscle; 2014 Mar; 5(1):27-34. PubMed ID: 24595460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: an overview.
    Ebner N; Elsner S; Springer J; von Haehling S
    Curr Opin Support Palliat Care; 2014 Mar; 8(1):15-24. PubMed ID: 24452279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference.
    Kung T; Springer J; Doehner W; Anker SD; von Haehling S
    Expert Opin Investig Drugs; 2010 Apr; 19(4):579-85. PubMed ID: 20367196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
    Anker MS; von Haehling S; Springer J; Banach M; Anker SD
    Arch Med Sci; 2013 Feb; 9(1):166-71. PubMed ID: 23515589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
    Emami A; Saitoh M; Valentova M; Sandek A; Evertz R; Ebner N; Loncar G; Springer J; Doehner W; Lainscak M; Hasenfuß G; Anker SD; von Haehling S
    Eur J Heart Fail; 2018 Nov; 20(11):1580-1587. PubMed ID: 30160804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
    Anker MS; von Haehling S; Springer J; Banach M; Anker SD
    Int J Cardiol; 2013 Jan; 162(2):73-6. PubMed ID: 23174169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The wasting continuum in heart failure: from sarcopenia to cachexia.
    von Haehling S
    Proc Nutr Soc; 2015 Nov; 74(4):367-77. PubMed ID: 26264581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs of Muscle Wasting and Their Therapeutic Targets.
    Sakuma K; Yamaguchi A
    Adv Exp Med Biol; 2018; 1088():463-481. PubMed ID: 30390265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal muscle wasting after a severe burn is a consequence of cachexia and sarcopenia.
    Song J; Clark A; Wade CE; Wolf SE
    JPEN J Parenter Enteral Nutr; 2021 Nov; 45(8):1627-1633. PubMed ID: 34296448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
    Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
    Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia and cachexia in chronic diseases: from mechanisms to treatment.
    Lena A; Hadzibegovic S; von Haehling S; Springer J; Coats AJ; Anker MS
    Pol Arch Intern Med; 2021 Dec; 131(12):. PubMed ID: 34775741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions.
    Holeček M
    J Cachexia Sarcopenia Muscle; 2017 Aug; 8(4):529-541. PubMed ID: 28493406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cachexia and sarcopenia: mechanisms and potential targets for intervention.
    Argilés JM; Busquets S; Stemmler B; López-Soriano FJ
    Curr Opin Pharmacol; 2015 Jun; 22():100-6. PubMed ID: 25974750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia.
    Hall DT; Ma JF; Marco SD; Gallouzi IE
    Aging (Albany NY); 2011 Aug; 3(8):702-15. PubMed ID: 21832306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs as potential therapeutic targets for muscle wasting during cancer cachexia.
    Sannicandro AJ; McDonagh B; Goljanek-Whysall K
    Curr Opin Clin Nutr Metab Care; 2020 May; 23(3):157-163. PubMed ID: 32073414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.